milestone everybody. major last carbidopa/levodopa. unmet need INBRIJA major on its was a in achievement Thanks, for the treatment of most INBRIJA the Felicia, OFF Parkinson’s a December of also year. approval and important and is Parkinson’s indicated OFF taking the The FDA people with is good known and by afternoon periods company intermittent This XXXX as episodes, community.
fact both approval in study XXXX, launch first the review And novel that of was particularly of people more highly systemic were which quality clinical targets a the is INBRIJA pivotal of Lancet trial The route. Parkinson’s. about pleased This given the in We INBRIJA device with by INBRIJA that the cycle later combination drug and I’ll this importance gratified detail condition presentation. results a published one by results a January journals. reflects were this neurology inhaled that of of the is the regarded and Phase most the III in to the the its We’re and Neurology,
XXXX range million $XX expect approximately cash million is to sheet. following full allow declines This company generics was sufficient the and the based introduction long revenue a in the significantly September projections. be strong year $XXX XXXX. continued in balance the We financial market AMPYRA on positive our to position to the declined for in on we to with the flow quarter sales Moving for fourth and ended $XXX year XXXX, million of
XX in the of action The measure our to is graph includes UPDRS as Part III, shows Parkinson’s the The assessed. single Turning which early as XX point label pleased is onset a primary graph with are INBRIJA, the to motor minutes outcome maintenance The for with time disease. effect long significance minutes, we strength a was the no approval function label. measure, – statistical of now of longest XX a XX which required. of dosage minutes titration milligrams and by
and open-label FEVX change no the which was mean data, to is included the measure difference safety year, also pulmonary Importantly, in went indicating that observational in cohorts. the INBRIJA safety one between there
on nine our experience learnings AMPYRA. highly and the Our builds over commercialization past successful strategy years with
Our neuro they commercial unmet therapy to highly industry medical regarded specialty and the a the with are of organization a one be introducing a in to need. well community motivated major new most patient is
quarter. to the put track on first We’re the channel drug in in
Our first of sales patient their field about and teams office been use inhaler staffs comprehensive and proper movement – specialists INBRIJA’s educate support have clinical our profile, medical disorder our meeting services. to and them the with
and education forms the prescription launched as programs. process we’ve speaker our training also called the with part request physicians reviewing PRFs We’re and of also
INBRIJA finding treatment and on-demand completed as We’re receptiveness to have PRF already strong OFF a received forms. for periods novel
to as programs their partners engage with Parkinson’s care people implementing are teams and well. Our
groups, educate the efficacy which the here about help with on community shown closely working the to We’re slide several of are INBRIJA.
what highly and a variable both people Parkinson’s. kit often for systemic OFF next advertising, the tools of part The targeted XX a allows or is of electronic management is the as XX branded due of need was daily events a few highly the lungs. INBRIJA. they in of expect and unique a to for regardless contains doses wholesale drug technology and with developed medication of disruptive required digital dry large within the ARCUS robust transforms relationship when delivered of time ARCUS is technology This route. the per about the maintenance are, a significant a educational can INBRIJA indication. the of molecules acquisition delivery welcome The consumers develop INBRIJA first said, page one that Parkinson’s INBRIJA weeks. treatment websites only is And Parkinson’s including of from customer through periods invented periods of MIT healthcare route. and periods also in and of including OFF community for I’ve in We’re time absorption the programs Bob INBRIJA, $XXX channel online to a self not regimen INBRIJA three doses for unpredictably. providers. to bypassing implementing ECRM therapy Langer. we’re least inhaled are The users be pulmonary through also community oral of treatment Facebook presence educate usually carton will lab inhaler non-pulmonary we over levodopa sponsoring into unmet one the major have occur powder allows the and OFF OFF oral innovation. and occur carton, It needed have periods at the in approved to the each treatments cost years INBRIJA
is Parkinson’s, INBRIJA appropriately. to main who One for support with priorities access can benefit people from of our
access to barriers as reduce much to as possible. working We’re
mitigation for to copay going those are who We insurance. have commercial provide
plans with We’re to did possible gain we’ll the we making seeking patient. AMPYRA formulary as be as plans as that collaborations clinical presentations win-win with to benefit quickly establish the access to insurance
INBRIJA of patient assess copay the going We’re of or incur pocket coinsurance allow patients to provide to out physicians costs. samples the has to their and before to value
system there Medicare, copay constraints that prohibit are on rely who assistance. built those into legal For the
address challenges help these possible. working patients as We’re constraints these within as to much for
aware best physicians be patients will have can of and office We they’re and access. which their their also plans they staffs, coverage communicating so help how get with
assist them possible, navigating in complex will will Our insurance hub we and understand much benefits patients as landscape. help services their the as
who are the have eligibility provide program. offices with are field on include and income a who drug also directors physicians They work we the free We of regimens augment hub. off our peak for there believe for people implementing with will reimbursement and INBRIJA issues, access help directly despite to This U.S. levodopa, with a are who experiencing team to uninsured carbidopa sales patient in regional we’re Parkinson’s meet exceed being million. that those requirements. about periods and XXX,XXX $XXX will In assistance
fourth and This quarter guidance $XXX the outlines year XXXX our priorities. to cash. year-end. in notably approximately key and we for Most financials Moving the with ended table million
pre-announced this Our earlier JP XXXX at Morgan year. guidance was expense
$XX be the full for R&D XXXX SG&A to $XX for to We expenses full to million the expenses and XXXX expect year $XXX million. million year be to million $XXX
is said a year. As provide to we don’t as XXXX previously we in guidance revenue launch expect INBRIJA this
to priorities XXXX. Moving our for
foremost, do are launch of a so. and that able to who First INBRIJA, as appropriately ensuring benefit with to ensure many successful people may Parkinson’s
therapies approval the continuing of also of plan partners. And ARCUS for are develop on obtain in of the this validated discuss to the and to looking technology. innovative indications. application additional INBRIJA our Europe EMAs now ex-U.S. the we platform the year. We approval We INBRIJA apply The ARCUS expect commercialization MAA potential to to collaborations has are by decision end with
least, and as look expenses and of and all on acute attention, your will is we to value. maintain treatment questions. resources on migraine, so milestones. shareholder to And controlling and you focus Thank updating most for operator, take forward will development deploying Our advanced we not maximize for our program you we finally, now
